Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Capital Expenditures: 2017-2024

Historic Capital Expenditures for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $933,000.

  • BridgeBio Pharma's Capital Expenditures rose 243.07% to $470,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 15.90%. This contributed to the annual value of $933,000 for FY2024, which is 28.56% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Capital Expenditures of $933,000 as of FY2024, which was down 28.56% from $1.3 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Capital Expenditures high stood at $13.2 million for FY2021, and its period low was $933,000 during FY2024.
  • Over the past 3 years, BridgeBio Pharma's median Capital Expenditures value was $1.3 million (recorded in 2023), while the average stood at $2.4 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Capital Expenditures surged by 184.99% in 2020, and later tumbled by 72.91% in 2023.
  • BridgeBio Pharma's Capital Expenditures (Yearly) stood at $7.5 million in 2020, then spiked by 76.19% to $13.2 million in 2021, then crashed by 63.60% to $4.8 million in 2022, then crashed by 72.91% to $1.3 million in 2023, then fell by 28.56% to $933,000 in 2024.